InterCure Ltd. (INCR)
USD 1.38
(-5.37%)
USD 1.38
(-5.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 102.84 Million ILS | -16.24% |
| 2022 | 122.78 Million ILS | 268.46% |
| 2021 | 33.32 Million ILS | 707.07% |
| 2020 | 4.12 Million ILS | 28.83% |
| 2019 | 3.2 Million ILS | 0.0% |
| 2018 | - ILS | 0.0% |
| 2017 | - ILS | 0.0% |
| 2016 | - ILS | 0.0% |
| 2015 | - ILS | 0.0% |
| 2014 | - ILS | 0.0% |
| 2013 | - ILS | 0.0% |
| 2012 | - ILS | 0.0% |
| 2011 | - ILS | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 51.31 Million ILS | 0.0% |
| 2024 Q1 | 51.31 Million ILS | -37.57% |
| 2023 Q3 | 102.84 Million ILS | -2.39% |
| 2023 Q2 | 105.36 Million ILS | -11.02% |
| 2023 FY | 102.84 Million ILS | -16.24% |
| 2023 Q1 | 118.4 Million USD | -3.56% |
| 2023 Q4 | 82.2 Million ILS | -20.07% |
| 2022 Q3 | 65 Million ILS | -3.68% |
| 2022 Q4 | 122.78 Million ILS | 88.88% |
| 2022 Q1 | 35.21 Million ILS | 5.69% |
| 2022 Q2 | 67.49 Million ILS | 91.63% |
| 2022 FY | 122.78 Million ILS | 268.46% |
| 2021 Q3 | 24.47 Million ILS | -37.87% |
| 2021 Q4 | 33.32 Million ILS | 36.16% |
| 2021 Q1 | 8.86 Million ILS | 114.7% |
| 2021 FY | 33.32 Million ILS | 707.07% |
| 2021 Q2 | 39.39 Million ILS | 344.4% |
| 2020 FY | 4.12 Million ILS | 28.83% |
| 2020 Q2 | 2.39 Million ILS | -6.95% |
| 2020 Q3 | 4.02 Million ILS | 68.16% |
| 2020 Q4 | 4.12 Million ILS | 2.48% |
| 2020 Q1 | 2.57 Million ILS | -19.66% |
| 2019 FY | 3.2 Million ILS | 0.0% |
| 2019 Q3 | 109 Thousand ILS | -80.32% |
| 2019 Q4 | 3.2 Million ILS | 2840.37% |
| 2019 Q1 | 109 Thousand ILS | 0.0% |
| 2019 Q2 | 554 Thousand ILS | 408.26% |
| 2018 Q2 | - ILS | 0.0% |
| 2018 Q3 | - ILS | 0.0% |
| 2018 Q4 | - ILS | 0.0% |
| 2018 FY | - ILS | 0.0% |
| 2018 Q1 | - ILS | 0.0% |
| 2017 Q1 | - ILS | 0.0% |
| 2017 Q3 | - ILS | 0.0% |
| 2017 Q4 | - ILS | 0.0% |
| 2017 FY | - ILS | 0.0% |
| 2017 Q2 | - ILS | 0.0% |
| 2016 Q3 | - ILS | 0.0% |
| 2016 FY | - ILS | 0.0% |
| 2016 Q4 | - ILS | 0.0% |
| 2016 Q2 | - ILS | 0.0% |
| 2016 Q1 | - ILS | 0.0% |
| 2015 Q4 | - ILS | 0.0% |
| 2015 Q3 | - ILS | 0.0% |
| 2015 Q1 | - ILS | 0.0% |
| 2015 FY | - ILS | 0.0% |
| 2015 Q2 | - ILS | 0.0% |
| 2014 Q4 | - ILS | 0.0% |
| 2014 Q3 | - ILS | 0.0% |
| 2014 Q2 | - ILS | 0.0% |
| 2014 Q1 | - ILS | 0.0% |
| 2014 FY | - ILS | 0.0% |
| 2013 Q4 | - ILS | 0.0% |
| 2013 FY | - ILS | 0.0% |
| 2013 Q1 | - ILS | 0.0% |
| 2013 Q2 | - ILS | 0.0% |
| 2013 Q3 | - ILS | 0.0% |
| 2012 FY | - ILS | 0.0% |
| 2012 Q2 | - ILS | 0.0% |
| 2012 Q3 | - ILS | 0.0% |
| 2012 Q4 | - ILS | 0.0% |
| 2012 Q1 | - ILS | 0.0% |
| 2011 Q1 | - ILS | 0.0% |
| 2011 FY | - ILS | 0.0% |
| 2011 Q2 | - ILS | 0.0% |
| 2011 Q3 | - ILS | 0.0% |
| 2011 Q4 | - ILS | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -671.747% |
| PainReform Ltd. | 30 Thousand USD | -342710.0% |
| Alvotech | 1.02 Billion USD | 89.994% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 79.01% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 66.789% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -12.92% |
| Journey Medical Corporation | 14.62 Million USD | -603.344% |
| Dynavax Technologies Corporation | 252.41 Million USD | 59.257% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 79.495% |
| Bright Green Corporation | 201.78 Thousand USD | -50867.128% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 79.984% |
| Embecta Corp. | 1.62 Billion USD | 93.673% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -18979.095% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -18979.095% |
| SCYNEXIS, Inc. | 12.15 Million USD | -745.818% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -1399.745% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -87703.191% |
| Alpha Teknova, Inc. | 13.25 Million USD | -676.115% |
| Safety Shot Inc | 304.9 Thousand USD | -33629.301% |
| Procaps Group, S.A. | 28.41 Million USD | -261.996% |
| Cosmos Health Inc. | 3.03 Million USD | -3288.186% |
| Theratechnologies Inc. | 51.26 Million USD | -100.626% |
| Harrow Health, Inc. | 183.17 Million USD | 43.854% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -118110.345% |
| Biofrontera Inc. | 804 Thousand USD | -12691.418% |
| DURECT Corporation | 2.7 Million USD | -3706.181% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -209.805% |
| Cronos Group Inc. | 1.55 Million USD | -6496.729% |
| OptiNose, Inc. | 611 Thousand USD | -16731.915% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 79.362% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -200.798% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -22502.857% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -69.303% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -704.457% |
| Radius Health, Inc. | 339.66 Million USD | 69.722% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -902.564% |
| Phibro Animal Health Corporation | 458.28 Million USD | 77.559% |
| Procaps Group S.A. | 28.41 Million USD | -261.996% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -1474.449% |
| Viatris Inc. | 16.18 Billion USD | 99.365% |
| Rockwell Medical, Inc. | 8.29 Million USD | -1140.118% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -845.509% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -30508.856% |
| Tilray Brands, Inc. | 287.93 Million USD | 64.283% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 14.66% |
| Shineco, Inc. | 10.01 Million USD | -926.651% |
| PetIQ, Inc. | 437.82 Million USD | 76.51% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -48872.857% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 60.185% |
| Alimera Sciences, Inc. | 64.48 Million USD | -59.474% |
| Assertio Holdings, Inc. | 38.51 Million USD | -167.028% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -76029.811% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -14183.75% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -457305.266% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -213.929% |
| Hempacco Co., Inc. | 5.93 Million USD | -1633.991% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 89.994% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -82.943% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 83.308% |
| Currenc Group, Inc. | 2.5 Million USD | -4002.276% |
| Kamada Ltd. | 7.43 Million USD | -1282.67% |
| Indivior PLC | 235.66 Million USD | 56.361% |
| Evoke Pharma, Inc. | 5 Million USD | -1956.86% |
| Flora Growth Corp. | 942 Thousand USD | -10817.516% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -457305.266% |
| Evolus, Inc. | 120.35 Million USD | 14.553% |
| HUTCHMED (China) Limited | 48.18 Million USD | -113.416% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 82.545% |
| Akanda Corp. | 2.49 Million USD | -4018.407% |